ReviewBreast cancer research : BCR2009
Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.
Review in Breast cancer research : BCR, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study.BMC cancer · 2014Trial
- Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast.Cancer · 2011Trial
- Translational Applications of Hydrogels.Chemical reviews · 2021Review
- Genomic alterations associated with HER2+ breast cancer risk and clinical outcome in response to trastuzumab.Molecular biology reports · 2019Article
- Article
- Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole.Therapeutic advances in medical oncology · 2018Article
- Clinical utility of gene-expression signatures in early stage breast cancer.Nature reviews. Clinical oncology · 2017Review
- Five-Year Disease-Free Follow-Up of a Borderline Breast Phyllodes Tumor in a 15-year-old Patient.The journal of breast health · 2015Article
- Genome-based risk prediction for early stage breast cancer.The oncologist · 2014Review
- Herceptin resistance database for understanding mechanism of resistance in breast cancer patients.Scientific reports · 2014Article
- The expression and clinical significance of HERC4 in breast cancer.Cancer cell international · 2013Article
- Nef-M1, a CXCR4 Peptide Antagonist, Enhances Apoptosis and Inhibits Primary Tumor Growth and Metastasis in Breast Cancer.Journal of cancer therapy · 2013Article
- HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma.Journal of cellular and molecular medicine · 2013Article
- Effect of HER2 status on distant recurrence in early stage breast cancer.Breast cancer research and treatment · 2013Article
- Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.PloS one · 2013Article
- Decreased total MKP-1 protein levels predict poor prognosis in breast cancer.World journal of surgery · 2012Article
- Coexistence of benign phyllodes tumor and invasive ductal carcinoma in distinct breasts: case report.European journal of medical research · 2012Article
- Molecular-targeted nanotherapies in cancer: enabling treatment specificity.Molecular oncology · 2011Review
- Photodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins.Pharmaceuticals (Basel, Switzerland) · 2011Article
- Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer.Journal of experimental & clinical cancer research : CR · 2011Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human epidermal growth factor receptor (HER)2 over-expression is associated with a shortened disease-free interval and poor survival. Although the addition of trastuzumab to chemotherapy in the first-line setting has improved response rates, progression-free survival, and overall survival, response rates declined when trastuzumab was used beyond the first-line setting because of multiple mechanisms of resistance. Studies have demonstrated the clinical utility of continuing trastuzumab beyond progression, and further trials to explore this concept are ongoing. New tyrosine kinase inhibitors, monoclonal antibodies, PTEN (phosphatase and tensin homolog) pathway regulators, HER2 antibody-drug conjugates, and inhibitors of heat shock protein-90 are being evaluated to determine whether they may have a role to play in treating trastuzumab-resistant metastatic breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.